Definium Therapeutics is trading 4.36% down at $43.18, with no clearly reported company-specific announcement explaining the August 11, 2026 decline.
- The company recently reported approximately $1.1 billion in cash and said Voyage generalized-anxiety results were expected during the week of August 10, making the pending readout an important near-term catalyst.
- Available reporting does not directly connect the readout to this morning’s move. Broader markets are mixed rather than sharply lower, and trading context is unavailable beyond the live quote.